☰

Raymond R. Mattingly - Publications

Affiliations: 
Pharmacology Wayne State University, Detroit, MI, United States 
Area:
Cell Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

58 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Reiners JJ, Mathieu PA, Gargano M, George I, Shen Y, Callaghan JF, Borch RF, Mattingly RR. Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. Cancers. 16. PMID 38201517 DOI: 10.3390/cancers16010089  0.428
2019 Ji K, Sameni M, Osuala K, Moin K, Mattingly RR, Sloane BF. Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer. Cancer Metastasis Reviews. PMID 31605250 DOI: 10.1007/S10555-019-09810-8  0.408
2019 Osuala KO, Ji K, Mattingly RR, Sloane BF. Breast Cancer: Proteolysis and Migration. Advances in Experimental Medicine and Biology. 1152: 401-411. PMID 31456196 DOI: 10.1007/978-3-030-20301-6_21  0.426
2018 Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR. Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia (New York, N.Y.). 20: 951-963. PMID 30144784 DOI: 10.1016/J.Neo.2018.07.002  0.406
2018 Brock EJ, Ji K, Shah S, Mattingly RR, Sloane BF. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ. Journal of Mammary Gland Biology and Neoplasia. PMID 30056557 DOI: 10.1007/S10911-018-9405-3  0.371
2018 Shah S, Brock EJ, Ji K, Mattingly RR. Ras and Rap1: A Tale of Two GTPases. Seminars in Cancer Biology. PMID 29621614 DOI: 10.1016/J.Semcancer.2018.03.005  0.392
2018 Brock EJ, Jackson R, Boerner JL, Li Q, Sloane BF, Mattingly RR. Abstract B14: Sprouty4 regulates the transition to invasive breast ductal carcinoma through ERK/MAPK signaling Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B14  0.386
2018 Ji K, Zhao Z, Moin K, Xu Y, Gillies RJ, Mattingly RR, Sloane BF. Abstract 2131: Paracrine cytokine pathways mediate metastasis of breast cancer to lymphatics Cancer Research. 78: 2131-2131. DOI: 10.1158/1538-7445.Am2018-2131  0.414
2017 Kraniak JM, Chalasani A, Wallace MR, Mattingly RR. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Experimental Neurology. PMID 29055717 DOI: 10.1016/J.Expneurol.2017.10.012  0.449
2017 Sameni M, Cavallo-Medved D, Franco OE, Chalasani A, Ji K, Aggarwal N, Anbalagan A, Chen X, Mattingly RR, Hayward SW, Sloane BF. Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. Breast Cancer Research : Bcr. 19: 56. PMID 28506312 DOI: 10.1186/S13058-017-0847-0  0.322
2017 Jackson RM, Brock EJ, Shah S, Sameni M, Sloane BF, Li Q, Mattingly RR. Abstract B28: Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B28  0.452
2016 Brock EJ, Ji K, Reiners JJ, Mattingly RR. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization. Mini Reviews in Medicinal Chemistry. 16: 358-69. PMID 26423696 DOI: 10.2174/1389557515666151001154002  0.365
2016 Brock EJ, Jackson R, Shah S, Li Q, Sameni M, Krawetz SA, Mao S, Sloane BF, Mattingly RR. Abstract 4560: Induced Sprouty4 expression in breast invasive ductal carcinoma cells downregulates ERK/MAPK activity and restores an epithelial-like phenotype Cancer Research. 76: 4560-4560. DOI: 10.1158/1538-7445.Am2016-4560  0.389
2015 Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, Hong Y, Hayward SW, Behbod F, Mattingly RR, Sloane BF. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. Bmc Cancer. 15: 584. PMID 26268945 DOI: 10.1186/S12885-015-1576-3  0.37
2014 Madden JM, Mueller KL, Bollig-Fischer A, Stemmer P, Mattingly RR, Boerner JL. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer. Breast Cancer Research and Treatment. 147: 283-93. PMID 25129346 DOI: 10.1007/S10549-014-3102-8  0.666
2014 Shah S, Osuala K, Mao S, Li Q, Sloane B, Krawetz S, Mattingly RR. Abstract 3150: Exploring the role of Rap1Gap in the progression from DCIS to invasive breast carcinoma Cancer Research. 74: 3150-3150. DOI: 10.1158/1538-7445.Am2014-3150  0.401
2013 Mattingly RR. Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. Isrn Oncology. 2013: 536529. PMID 24294527 DOI: 10.1155/2013/536529  0.357
2013 Rothberg JM, Bailey KM, Wojtkowiak JW, Ben-Nun Y, Bogyo M, Weber E, Moin K, Blum G, Mattingly RR, Gillies RJ, Sloane BF. Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia (New York, N.Y.). 15: 1125-37. PMID 24204192 DOI: 10.1593/Neo.13946  0.712
2013 Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. The Journal of Clinical Investigation. 123: 4449-63. PMID 24091327 DOI: 10.1172/Jci67509  0.35
2013 Kaur H, Mao S, Shah S, Gorski DH, Krawetz SA, Sloane BF, Mattingly RR. Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Review of Molecular Diagnostics. 13: 151-65. PMID 23477556 DOI: 10.1586/Erm.13.4  0.552
2013 Hammer A, Rider L, Oladimeji P, Cook L, Li Q, Mattingly RR, Diakonova M. Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A. Molecular Endocrinology (Baltimore, Md.). 27: 455-65. PMID 23340249 DOI: 10.1210/Me.2012-1291  0.366
2012 Kaur H, Mao S, Li Q, Sameni M, Krawetz SA, Sloane BF, Mattingly RR. RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target. Plos One. 7: e50249. PMID 23236365 DOI: 10.1371/Journal.Pone.0050249  0.605
2012 Sameni M, Anbalagan A, Olive MB, Moin K, Mattingly RR, Sloane BF. MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression Journal of Visualized Experiments : Jove. PMID 22371028 DOI: 10.3791/3661  0.417
2012 Moin K, Sameni M, Victor BC, Rothberg JM, Mattingly RR, Sloane BF. 3D/4D functional imaging of tumor-associated proteolysis: impact of microenvironment. Methods in Enzymology. 506: 175-94. PMID 22341225 DOI: 10.1016/B978-0-12-391856-7.00034-2  0.377
2011 Wojtkowiak JW, Sane KM, Kleinman M, Sloane BF, Reiners JJ, Mattingly RR. Aborted autophagy and nonapoptotic death induced by farnesyl transferase inhibitor and lovastatin. The Journal of Pharmacology and Experimental Therapeutics. 337: 65-74. PMID 21228063 DOI: 10.1124/Jpet.110.174573  0.677
2011 Sloane B, Sameni M, Anbalagan A, Olive M, Shokoohi N, Moin K, Mattingly R. 4D MAME Models for Live-Cell Imaging of Interactions Between Breast Tumor Cells and Their Microenvironment Microscopy and Microanalysis. 17: 62-63. DOI: 10.1017/S1431927611001188  0.371
2010 Kraniak JM, Sun D, Mattingly RR, Reiners JJ, Tainsky MA. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors. Molecular and Cellular Biochemistry. 344: 267-76. PMID 20680410 DOI: 10.1007/S11010-010-0551-1  0.426
2010 Sane KM, Mynderse M, Lalonde DT, Dean IS, Wojtkowiak JW, Fouad F, Borch RF, Reiners JJ, Gibbs RA, Mattingly RR. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autophagy in STS-26T MPNST cells. The Journal of Pharmacology and Experimental Therapeutics. 333: 23-33. PMID 20086055 DOI: 10.1124/Jpet.109.160192  0.69
2010 Li Q, Chow AB, Mattingly RR. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 332: 821-8. PMID 19952304 DOI: 10.1124/Jpet.109.160390  0.469
2010 Sun D, Kraniak J, Mattingly R, Tainsky MA. Abstract 4977: Identification of transcriptional mechanisms specific to of NF1 gene deficiency Cancer Research. 70: 4977-4977. DOI: 10.1158/1538-7445.Am10-4977  0.36
2009 Wojtkowiak JW, Gibbs RA, Mattingly RR. Working together: Farnesyl transferase inhibitors and statins block protein prenylation. Molecular and Cellular Pharmacology. 1: 1-6. PMID 20419048 DOI: 10.4255/Mcpharmacol.09.01  0.733
2009 Wojtkowiak JW, Gibbs RA, Mattingly RR. Working together: Farnesyl transferase inhibitors and statins block protein prenylation Molecular and Cellular Pharmacology. 1: 1-6. DOI: 10.4255/mcpharmacol.09.01  0.675
2008 Li Q, Mattingly RR. Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. Neoplasia (New York, N.Y.). 10: 1444-58. PMID 19048123 DOI: 10.1593/Neo.08968  0.421
2008 Dilworth JT, Wojtkowiak JW, Mathieu P, Tainsky MA, Reiners JJ, Mattingly RR, Hancock CN. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer Biology & Therapy. 7: 1938-46. PMID 18927496 DOI: 10.4161/Cbt.7.12.6942  0.78
2008 Li Q, Mullins SR, Sloane BF, Mattingly RR. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia (New York, N.Y.). 10: 314-29. PMID 18392133 DOI: 10.1593/Neo.07970  0.44
2008 Wojtkowiak JW, Fouad F, LaLonde DT, Kleinman MD, Gibbs RA, Reiners JJ, Borch RF, Mattingly RR. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. The Journal of Pharmacology and Experimental Therapeutics. 326: 1-11. PMID 18367665 DOI: 10.1124/Jpet.107.135830  0.745
2008 Moin K, Sameni M, Jedeszko C, Li Q, Olive MB, Mattingly RR, Sloane BF. Images of cleavage: Tumor proteases in action The Cancer Degradome: Proteases and Cancer Biology. 137-154. DOI: 10.1007/978-0-387-69057-5_8  0.335
2007 McCabe MJ, Laiosa MD, Li L, Menard SL, Mattingly RR, Rosenspire AJ. Low and nontoxic inorganic mercury burdens attenuate BCR-mediated signal transduction. Toxicological Sciences : An Official Journal of the Society of Toxicology. 99: 512-21. PMID 17656488 DOI: 10.1093/Toxsci/Kfm188  0.356
2007 Clark MK, Scott SA, Wojtkowiak J, Chirco R, Mathieu P, Reiners JJ, Mattingly RR, Borch RF, Gibbs RA. Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. Journal of Medicinal Chemistry. 50: 3274-82. PMID 17555307 DOI: 10.1021/Jm0701829  0.741
2007 Norum JH, Dawood H, Mattingly RR, Sandnes D, Levy FO. Epac- and Rap- independent ERK1/2 phosphorylation induced by Gs-coupled receptor stimulation in HEK293 cells. Febs Letters. 581: 15-20. PMID 17174312 DOI: 10.1016/J.Febslet.2006.11.069  0.34
2006 Dilworth JT, Kraniak JM, Wojtkowiak JW, Gibbs RA, Borch RF, Tainsky MA, Reiners JJ, Mattingly RR. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1. Biochemical Pharmacology. 72: 1485-92. PMID 16797490 DOI: 10.1016/J.Bcp.2006.04.010  0.771
2006 Yang H, Mattingly RR. The Ras-GRF1 exchange factor coordinates activation of H-Ras and Rac1 to control neuronal morphology. Molecular Biology of the Cell. 17: 2177-89. PMID 16481401 DOI: 10.1091/Mbc.E05-10-0913  0.309
2006 Ziemba SE, Mattingly RR, McCabe MJ, Rosenspire AJ. Inorganic mercury inhibits the activation of LAT in T-cell receptor-mediated signal transduction. Toxicological Sciences : An Official Journal of the Society of Toxicology. 89: 145-53. PMID 16251484 DOI: 10.1093/Toxsci/Kfj029  0.426
2006 Mattingly RR, Kraniak JM, Dilworth JT, Mathieu P, Bealmear B, Nowak JE, Benjamins JA, Tainsky MA, Reiners JJ. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines. The Journal of Pharmacology and Experimental Therapeutics. 316: 456-65. PMID 16239399 DOI: 10.1124/Jpet.105.091454  0.685
2005 Menard RE, Jovanovski AP, Mattingly RR. Active p21-activated kinase 1 rescues MCF10A breast epithelial cells from undergoing anoikis. Neoplasia (New York, N.Y.). 7: 638-45. PMID 16026643 DOI: 10.1593/Neo.04736  0.456
2005 Norum JH, Méthi T, Mattingly RR, Levy FO. Endogenous expression and protein kinase A-dependent phosphorylation of the guanine nucleotide exchange factor Ras-GRF1 in human embryonic kidney 293 cells. The Febs Journal. 272: 2304-16. PMID 15853814 DOI: 10.1111/J.1742-4658.2005.04658.X  0.351
2004 Chopra DP, Menard RE, Januszewski J, Mattingly RR. TNF-alpha-mediated apoptosis in normal human prostate epithelial cells and tumor cell lines. Cancer Letters. 203: 145-54. PMID 14732222 DOI: 10.1016/J.Canlet.2003.09.016  0.366
2004 Menard RE, Mattingly RR. Gbetagamma subunits stimulate p21-activated kinase 1 (PAK1) through activation of PI3-kinase and Akt but act independently of Rac1/Cdc42. Febs Letters. 556: 187-92. PMID 14706848 DOI: 10.1016/S0014-5793(03)01406-6  0.376
2003 Menard RE, Mattingly RR. Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways. Cellular Signalling. 15: 1099-109. PMID 14575865 DOI: 10.1016/S0898-6568(03)00087-1  0.364
2003 Mattingly RR. Mitogen-activated protein kinase signaling in drug-resistant neuroblastoma cells. Methods in Molecular Biology (Clifton, N.J.). 218: 71-83. PMID 12616713 DOI: 10.1385/1-59259-356-9:71  0.405
2002 Mattingly RR, Gibbs RA, Menard RE, Reiners JJ. Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. The Journal of Pharmacology and Experimental Therapeutics. 303: 74-81. PMID 12235235 DOI: 10.1124/Jpet.102.036061  0.404
2002 Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta. The Journal of Biological Chemistry. 277: 22558-65. PMID 11960991 DOI: 10.1074/Jbc.M202351200  0.343
2002 Beqaj S, Jakkaraju S, Mattingly RR, Pan D, Schuger L. High RhoA activity maintains the undifferentiated mesenchymal cell phenotype, whereas RhoA down-regulation by laminin-2 induces smooth muscle myogenesis. The Journal of Cell Biology. 156: 893-903. PMID 11877460 DOI: 10.1083/Jcb.200107049  0.387
2001 Mattingly RR, Felczak A, Chen CC, McCabe MJ, Rosenspire AJ. Low concentrations of inorganic mercury inhibit Ras activation during T cell receptor-mediated signal transduction. Toxicology and Applied Pharmacology. 176: 162-8. PMID 11714248 DOI: 10.1006/Taap.2001.9272  0.393
2001 Mattingly RR, Milstein ML, Mirkin BL. Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells. Cellular Signalling. 13: 499-505. PMID 11516625 DOI: 10.1016/S0898-6568(01)00173-5  0.431
1999 Mattingly RR. Phosphorylation of serine 916 of Ras-GRF1 contributes to the activation of exchange factor activity by muscarinic receptors. The Journal of Biological Chemistry. 274: 37379-84. PMID 10601308 DOI: 10.1074/Jbc.274.52.37379  0.345
1999 Mattingly RR, Saini V, Macara IG. Activation of the Ras-GRF/CDC25Mm exchange factor by lysophosphatidic acid. Cellular Signalling. 11: 603-10. PMID 10433521 DOI: 10.1016/S0898-6568(99)00034-0  0.331
1996 Wilson DJ, Fortner KA, Lynch DH, Mattingly RR, Macara IG, Posada JA, Budd RC. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells. European Journal of Immunology. 26: 989-94. PMID 8647190 DOI: 10.1002/eji.1830260505  0.366
Show low-probability matches.